1. Generics Bulletin

What Aspects Will Give Humira Biosimilars The Edge In 2023?

Vizient Report Examines Views Of Pharmacy Executives And Professionals

 
• By Dave Wallace

With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.

Horse race leader
As US Humira biosimilars approach launch, which are best positioned? • Source: Shutterstock

With multiple Humira (adalimumab) biosimilars expected to hit the US market in 2023, all eyes are on the approved and yet-to-be-approved products that are set to launch, with great interest in seeing how competition will play out for such a unique loss-of-exclusivity opportunity.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products